GIBSON DUNN

Gibson Dunn Advises Dianthus Therapeutics on $719 Million Upsized Offering of Common Stock and Pre-Funded Warrants

Firm News | March 17, 2026

Gibson Dunn represented Dianthus Therapeutics, Inc. on a public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The offering generated aggregate gross proceeds of approximately $719 million to Dianthus.

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. The company is headquartered in New York.

Gibson Dunn regularly advises clinical-stage biotechnology companies on capital markets offerings in the life sciences sector.

The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Nicholas Linke, Jasmine Vitug, and Lauren Guzman.

Related Capabilities

Capital Markets

Life Sciences

Related People

Ryan A. Murr

Branden C. Berns

Melanie E. Neary

Nicholas G. Linke

Jasmine L. Vitug

Lauren Guzman

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**